Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alexion | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Alexion

Soliris sales continue to climb

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Financial Report: Alexion 4Q13

4Q Revenues: $442 million (+38%)

4Q Loss: $19 million (earnings of $81 million in 4Q12)

FY Revenues: $1.6 billion (+37%)

FY Earnings: $253 million (-1%)

Comments: Sales of the company’s sole commercial product, Soliris, continued to grow as it added new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion took a $153 million charge during FY13 in connection with centralizing certain business operations, impairment of intangible assets, expenses from license agreements, and an intellectual property settlement; $129 million of that was incurred in 4Q13, leading to a net loss.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics